

## Bevenopran

## Chemical Properties


CAS No. : 676500-67-7

Formula: C<sub>20</sub>H<sub>26</sub>N<sub>4</sub>O<sub>4</sub>

Molecular Weight: 386.44

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

Actual storage temperature shall be subject to the COA.



## Biological Description

Description	Bevenopran (CB-5945) is a peripheral antagonist of $\mu$ -opioid receptor and can be used in studies about the treatment of opioid-induced bowel dysfunction.
Targets(IC <sub>50</sub> )	Opioid Receptor
In vivo	Bevenopran tends to increase bowel movement (BM) frequency, especially for 0.1 mg twice daily and 4 mg daily, respectively[1].

## Solubility Information

Solubility	DMSO: 120 mg/mL (310.53 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween 80+45% Saline: 4 mg/mL (10.35 mM),Sonication is recommended. <i>Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.</i>

### Preparing Stock Solutions

---

	<b>1mg</b>	<b>5mg</b>	<b>10mg</b>
1 mM	2.5877 mL	12.9386 mL	25.8772 mL
5 mM	0.5175 mL	2.5877 mL	5.1754 mL
10 mM	0.2588 mL	1.2939 mL	2.5877 mL
50 mM	0.0518 mL	0.2588 mL	0.5175 mL

---

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

### Reference

Diego L, et al. Novel opioid antagonists for opioid-induced bowel dysfunction. *Expert Opin Investig Drugs*. 2011 Aug;20(8):1047-56.

Siemens W, et al. Advances in pharmacotherapy for opioid-induced constipation - a systematic review. *Expert Opin Pharmacother*. 2015 Mar;16(4):515-32.

**Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins**

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E\_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481